The case for & against
Bull & Bear analysis
Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a biotechnology company focused on developing cytosinicline, a novel treatment for nicotine dependence. Positioned to change the landscape of smoking cessation therapies, Achieve aims to address a significant public health concern affecting millions of Americans, particularly given the lack of new FDA-approved treatment options for over two decades. With recent advancements, including regulatory milestones and strategic partnerships, Achieve is entering a transformative phase as it prepares for a commercial launch targeting both smoking and vaping cessation markets.
Bull says
- ↑Raised $180M in private placement, funding operations through NDA resubmission
- ↑Cytosinicline showed 32.4% continuous abstinence vs. 6% placebo in trials
- ↑Received national priority review voucher, potentially speeding FDA approval
- ↑Addresses a 50M adult nicotine user market, including 25M smokers
- ↑Strong short-term momentum and high earnings revision factors support stock
- ↑Low leverage factors highlight a conservative balance sheet position
Bear says
- ↓2025 net loss of $54.7M and $14.7M in operating costs drive cash burn
- ↓Cash runway of $55.4M only funds operations into mid-2026
- ↓FDA approval uncertainty could delay the expected 2027 launch
- ↓Chantix reentry and established therapies pose competitive threats
- ↓Weak profitability and quality factors signal potential downward pressure
- ↓High volatility and elevated short interest reflect investor skepticism
Investment themes with ACHV
Genetic and drug innovations driving medical breakthroughs
Stocks with highest short interest
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- our principal goal and my principal goal is completing that tech transfer to Adair on as fast a timeline as possible while maintaining our completeness. Importantly, now we have the resources to do so, and we recognize what's at stake. The patients waiting for this medicine can't afford for us to get this wrong, and so we will ramp up where it's needed to get this right.
- So yes, after our financing, which we closed, we're in a very strong financial position to be able to execute on our goals and our launch preparation. So we have the resources now that we need to execute on a broader commercial strategy.
- We are developing a new treatment for cessation of smoking, the leading cause of preventable death, as well as vaping that is putting a new generation at risk.
Bear points
- two Phase III double-blind placebo-controlled trials where Not one, but both of our six and 12-week courses reach statistical significance.